Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Yokomizo Hisashi Last modified date:2021.08.05

Assistant Professor / Department of Endocrine and Metabolic Diseases / Diabetes Mellitus / Kyushu University Hospital

1. H. Yokomizo, Y. Maeda, K. Park, A. Clermont, S. Hernandez, W. Fickweiler, Q. Li, C. Wang, S. Paniagua, F. Simao, A. Ishikado, B. Sun, I. Wu, S. Katagiri, D. Pober, L. Tinsley, R. Avery, E. Feener, T. Kern, H. Keenan, L. Aiello, J. Sun, and GL. King. , Retinol Binding Protein 3 is increased in the retina of diabetic patients resistant to diabetic retinopathy., Science Translational Medicine, Sci Transl Med. 11 (499): Jul 3, 2019., 2019.07, The Joslin Medalist Study characterized people affected with type 1 diabetes for 50 years or longer. Over 35% of these individuals exhibit no to mild diabetic retinopathy (DR), independent of glycemic control, suggesting the presence of endogenous protective factors against DR in a subpopulation of patients. Proteomic analysis of retina and vitreous identified Retinol Binding Protein 3 (RBP3), a retinol transport protein secreted mainly by the photoreceptors, as elevated in medalist patients protected from advanced DR. Mass spectrometry and protein expression analysis identified an inverse association between vitreous RBP3 concentration and DR severity. Intravitreous injection and photoreceptor-specific overexpression of RBP3 in rodents inhibited the detrimental effects of vascular endothelial growth factor (VEGF). Mechanistically, our results showed that recombinant RBP3 exerted the therapeutic effects by binding to and inhibiting VEGF receptor tyrosine phosphorylation. In addition, by binding to GLUT1 and decreasing glucose uptake, RBP3 blocked the detrimental effects of hyperglycemia on inducing inflammatory cytokines in retinal endothelial and Müller cells. Elevated expression of photoreceptor-secreted RBP3 may have a role in protection against the progression of DR due to hyperglycemia by inhibiting glucose uptake via GLUT1 and decreasing the expression of inflammatory cytokines and VEGF..
2. H. Yokomizo, T. Inoguchi, N. Sonoda, Y. Sakaki, Y. Maeda, T. Inoue, E. Hirata, R. Takei, N. Ikeda, M. Fujii, K. Fukuda, H. Sasaki, and R. Takayanagi., Maternal high-fat diet induces insulin resistance and deterioration of pancreatic ß-cell function in adult offspring with sex differences in mice., American Journal of Physiology-Endocrinology and Metabolism, Am J Physiol Endocrinol Metab. 306: E1163-E1175, 2014., 2014.05.
3. Q. Li, J. Fu, X. Yu, Q. Weier, A. Ishikado, K. Park, H. Yokomizo, H. Qian, C. Weikang, C. Rask-Madsen, CR. Kahn, and GL. King. , Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes. , Nature Communications, 10.1038, 10, 1, 2019.09.
4. Kentaro Abe, Yasutaka Maeda, Chitose Matsuzaki, Hisashi Yokomizo, Tomoaki Inoue, Noriyuki Sonoda, Yoshihiro Ogawa, Toyoshi Inoguchi, Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study, Journal of Diabetes Investigation, doi: 10.1111/jdi.13568, 2021.05.
5. K. Park, Q. Li, ND. Evcimen, C. Rask-Madsen, Y. Maeda, E. Maddaloni, H. Yokomizo, T. Shinjo, R. St-Louis, J. Fu, D. Gordin, M. Khamaisi, D. Pober, H. Keenan, and GL. King., Exogenous insulin infusion can decrease atherosclerosis in diabetic rodents by improving lipids, inflammation, and endothelial function. , Arteriosclerosis Thrombosis and Vascular Biology, Arterioscler Thromb Vasc Biol. 38:92-101, 2018., 2018.01.
6. Q. Li, K. Park, Y. Xia, M. Matsumoto, W. Qi, J. Fu, H. Yokomizo, M. Khamaisi, X. Wang, C. Rask-Madsen, and GL. King. , Regulation of macrophage apoptosis and atherosclerosis by lipid induced PKCδ isoform activation. , Circulation Research, Circ Res. 121:1153-1167, 2017., 2017.10.
7. S. Katagiri, K. Park, Y. Maeda, TN. Rao, M. Khamaisi, Q. Li, H. Yokomizo, A. Mima, L. Lancerotto, A. Wagers, DP. Orgill, and GL. King. , Overexpressing IRS1 in endothelial cells enhances angioblast differentiation and wound healing in diabetes and insulin resistance. , Diabetes, Diabetes. 65: 2760-2771, 2016., 2016.09.
8. T. Inoue, T. Inoguchi, N. Sonoda, H. Hendarto, H. Makimura, S. Sasaki, H. Yokomizo, Y. Fujimura, D. Miura, and R. Takayanagi., GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats., Atherosclerosis, 2015.05.
9. H. Hendarto, T. Inoguchi, Y. Maeda, N. Ikeda, J. Zheng, R. Takei, H. Yokomizo, E. Hirata, N. Sonoda, and R. Takayanagi. , GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases., Metabolism, Metabolism. 61: 1422-1434, 2012., 2012.10.
10. S. Kimura, T. Inoguchi, H. Yokomizo, Y. Maeda, N Sonoda, and R. Takayanagi. , Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. , Diabetes, Obesity & Metabolism, Diabetes Obes Metab.14: 666-669, 2012., 2012.07.
11. N. Ikeda, T. Inoguchi, N. Sonoda, M. Fujii, R. Takei, E. Hirata, H. Yokomizo, J. Zheng, Y. Maeda, K. Kobayashi, and R. Takayanagi., Biliverdin protects against the deterioration of glucose tolerance in db/db mice., Diabetologia, Diabetologia. 54: 2183-2191, 2011., 2011.08.